Allist Pharmaceuticals, Inc.

This study tests an experimental pill called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation and have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and con…

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…

This study tests whether a new drug called furmonertinib, when combined with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous non-small cell lung cancer) that has spread to the brain. Ab…

This early-stage study tests a new tablet (AST2303) in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants must have…